122 related articles for article (PubMed ID: 3308485)
21. [Comparative studies of the antitumor activities of CDDP and the analogs--using gynecological carcinomas transplanted into nude mice].
Suzumori K; Yasui Y; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):387-91. PubMed ID: 2649007
[TBL] [Abstract][Full Text] [Related]
22. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
23. Carboplatin in the first-line chemotherapy of ovarian cancer.
Alberts DS; Canetta R; Mason-Liddil N
Semin Oncol; 1990 Feb; 17(1 Suppl 2):54-60. PubMed ID: 2406922
[TBL] [Abstract][Full Text] [Related]
24. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
25. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
26. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
[TBL] [Abstract][Full Text] [Related]
27. [Comparative studies of antitumor activities of oxalate (1R, 2R-cyclohexanediammine) platinum (II) and cis-dichlorodiammine-platinum (II) using ovarian cancer transplanted into nude mice].
Suzumori K; Yasui Y; Asai H; Yagami Y
Gan To Kagaku Ryoho; 1986 Feb; 13(2):280-5. PubMed ID: 3947107
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
29. Response of nude mouse-grown adenocarcinomas of the human exocrine pancreas to cis-diamminedichloroplatinum(II), diammine[1,1-cyclobutanedicarboxylato(2-)-O,O'-platinum], and mitoguazone dihydrochloride.
Kyriazis AP; Kyriazis AA; Yagoda A; Fogh J
Cancer Res; 1985 Sep; 45(9):4354-9. PubMed ID: 3896479
[TBL] [Abstract][Full Text] [Related]
30. [Antitumor activity of cisplatin and carboplatin against human tumor xenografts serially transplanted into nude mice--with special reference to gastric carcinomas].
Shimoyama Y; Kubota T; Inoue S; Kuzuoka M; Ohishi T; Oka S; Kikuyama S; Ishibiki K; Abe O
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2682-7. PubMed ID: 3307633
[TBL] [Abstract][Full Text] [Related]
31. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
[TBL] [Abstract][Full Text] [Related]
32. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
33. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
34. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.
Jarvis IW; Meczes EL; Thomas HD; Edmondson RJ; Veal GJ; Boddy AV; Ottley CJ; Pearson DG; Tilby MJ
Biochem Pharmacol; 2012 Jan; 83(1):69-77. PubMed ID: 22015635
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
[TBL] [Abstract][Full Text] [Related]
36. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
Jones M; Siracky J; Kelland LR; Harrap KR
Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
[TBL] [Abstract][Full Text] [Related]
37. Comparing cisplatin and carboplatin.
Neijt JP; van Houwelingen JC
J Natl Cancer Inst; 1990 Mar; 82(5):434-5. PubMed ID: 2406453
[No Abstract] [Full Text] [Related]
38. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin in refractory epithelial ovarian cancer.
Kavanagh JJ; Nicaise C
Semin Oncol; 1989 Apr; 16(2 Suppl 5):45-8. PubMed ID: 2655098
[No Abstract] [Full Text] [Related]
40. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
